SOUTH SAN FRANCISCO, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that it will host a Research and Development (R&D) Day for analysts and investors on Tuesday, October 30, 2018 beginning at 8:00 a.m. ET (5:00 a.m. PT) in New York City.
In addition to presentations by MyoKardia’s management team, which will review the company’s precision medicine approach to drug discovery and development and provide updates on its clinical and emerging research pipeline, the R&D Day will feature presentations from key opinion leaders (KOLs) in the field of rare cardiovascular diseases. Presenting KOLs include:
- Nancy Sweitzer, M.D., Ph.D., Director of the University of Arizona’s Sarver Heart Center and professor of medicine and chief of the Division of Cardiology in the University of Arizona College of Medicine-Tuscon
- Carolyn Yung Ho, M.D., Medical Director of the Cardiovascular Genetics Center at Brigham and Women’s Hospital and associate professor of medicine at Harvard Medical School
- Christine (Kricket) Seidman, M.D., Thomas W. Smith Professor of Medicine at Harvard Medical School and Brigham and Women’s Hospital.
Analysts, investors and interested members of the public may access the live webcast of MyoKardia’s R&D Day presentation, by visiting the “Events & Presentations” page within the Investors & Media section of the MyoKardia website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia website for [90] days following the event.
About MyoKardia
MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of two of the most prevalent forms of heritable cardiomyopathy – hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). MyoKardia’s most advanced product candidate is mavacamten (formerly MYK-461), a novel, oral, allosteric modulator of cardiac myosin intended to reduce hypercontractility. Mavacamten is being studied in a pivotal Phase 3 clinical trial, known as EXPLORER-HCM, in patients with symptomatic, obstructive HCM. MyoKardia is also developing mavacamten in a second indication, non-obstructive HCM, in the Phase 2 MAVERICK-HCM clinical trial. MYK-491, MyoKardia’s second product candidate, is designed to increase the overall extent of the heart’s contraction in DCM patients by increasing cardiac contractility. MyoKardia is currently evaluating MYK-491 in a Phase 1b study in DCM patients. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science. For more information, please visit www.myokardia.com.